Saturday 17 October 2026 Export AGL’s income statement to Excel — free account

Agilon Health, Inc.

Agilon Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.9 billion, down 2.11% from fiscal 2024. In the quarter to June 2026, revenue grew 7.15%, EPS grew 117.1%, free cash flow fell 50.2% and total debt fell 13.3%, each against the same quarter a year earlier. Dividend growth for five consecutive years; insiders bought in the last twelve months.

85.12 3.33 −3.76%

Follow AGL

Alert me

Market cap: $1.5B
P/E: 0.0×
Fwd P/E: −33.1×
Dividend yield: —
F-score: 3/9
Altman Z: 1.45
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.35

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	4	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 29.84%

Capital & Financial Ratios $m

Market Cap 1,490.00

Revenue 5,920.02

Net Income (232.22)

Free Cash Flow (105.98)

Net Debt (226.96)

Current Ratio 1.08

Debt/Equity 0.13

P/E ratio 0.00

Fwd P/E (33.10)

P/S ratio 0.24

P/B ratio 6.25

Past 5Y EPS Growth —

This Y EPS Growth 90.51%

Next Y EPS Growth 174.27%

Next Y revenue growth 10.36%

Next 5Y EPS Growth 79.96%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 26.52%

10-year low 10-year high

P/B against its own 10 years 50.34%

10-year low 10-year high

EV/Sales against its own 10 years 26.35%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	495	406	285	257
Receivables	942	1,017	674	1,060
Inventory	—	—	—	—
Other	—	—	—	—
	1,480	1,458	1,097	1,419

	2023	2024	2025	Q'26
Payables	239	220	127	275
ST’ Debt	6	—	19	15
Other	—	—	—	—
	977	1,152	1,076	1,312

Compound Annual Growth %

	10y	5y	3y
Sales	22.28%	37.24%	35.43%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	(50.43%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,420	1,495	—	—	—
’25	1,533	1,395	1,435	1,569	5,933
’24	1,604	1,483	1,451	1,522	6,061
’23	1,054	1,069	1,137	1,056	4,316
’22	653	670	695	370	2,388
’21	413	499	459	151	1,521
’20	291	294	313	321	1,218

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	24	(57)	—	—	—
’25	(32)	(35)	(18)	(21)	(106)
’24	(48)	(19)	(8)	16	(58)
’23	(61)	(21)	(13)	(61)	(156)
’22	(23)	(60)	3	(50)	(131)
’21	(41)	(39)	(19)	(49)	(148)
’20	(26)	(9)	(4)	(13)	(53)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	21	(62)	—	—	—
’25	(43)	(41)	(35)	(30)	(149)
’24	(62)	(28)	(12)	4	(99)
’23	(65)	(27)	(19)	(77)	(187)
’22	(28)	(76)	(1)	(58)	(163)
’22	—	—	—	—	(131)
’21	(45)	(40)	(24)	(52)	(162)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	2.94	1.04	—	—	—
’25	0.75	(6.25)	(6.75)	(11.50)	(23.75)
’24	(0.25)	(1.75)	(7.25)	(6.50)	(15.75)
’23	1.00	(1.00)	(2.00)	(14.25)	(16.00)
’22	0.00	(1.25)	(1.75)	(3.50)	(6.50)
’21	(1.25)	(19.75)	(2.25)	(3.50)	(27.25)
’20	(1.25)	(0.61)	(0.91)	(1.87)	(4.64)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	520.25	359.00	260.25	37.50	12.70	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	1,120.75	709.00	736.00	332.00	152.00
People
People	Employees	—	—	—	—	552	648	747	1,117	1,076	856
	Revenue/emp, $m	—	—	—	0.00	2.21	2.35	3.20	3.86	5.63	6.93
Income, $m
Income, $m	Revenue	—	—	—	794	1,218	1,521	2,388	4,316	6,061	5,933
	Gross margin, %	—	—	—	3.59	7.73	4.32	4.66	1.61	0.08	(2.70)
	EBT	—	—	—	(115)	(62)	(383)	(91)	(194)	(249)	(404)
	EBT margin, %	—	—	—	(14.44)	(5.12)	(25.17)	(3.80)	(4.51)	(4.11)	(6.81)
	Net income	—	0	—	(283)	(60)	(407)	(107)	(263)	(260)	(391)
	Depreciation	—	—	—	41	14	15	14	20	24	29
Per share, $
Per share, $	Revenue	—	—	—	67.38	94.16	102.00	146.28	263.89	368.68	358.27
	Earnings	—	—	—	(23.98)	(4.64)	(27.25)	(6.50)	(16.00)	(15.75)	(23.75)
	Cash flow	—	—	—	(8.81)	(4.11)	(9.93)	(8.01)	(9.55)	(3.51)	(6.39)
	Capex	—	—	—	(0.33)	(0.18)	(0.90)	(2.00)	(1.88)	(2.51)	(2.60)
	Free cash flow	—	—	—	(9.14)	(4.29)	(10.83)	(10.01)	(11.43)	(6.03)	(8.99)
	Book value	—	—	—	(19.68)	(22.01)	73.18	63.74	40.41	28.65	7.65
	Shares, m	—	—	—	12	13	15	16	16	16	17
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	7.53	7.53	6.62	2.74	1.22	0.13	0.05
	P/B	—	—	—	0.00	0.00	9.22	6.29	8.00	1.66	2.25
	EV/Sales	—	—	—	7.52	7.52	5.96	2.39	1.12	0.07	0.01
	EV/FCF	—	—	—	(136.12)	(136.12)	(56.09)	(34.88)	(25.18)	(4.23)	(0.24)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(104)	(53)	(148)	(131)	(156)	(58)	(106)
	Capex	—	—	—	(4)	(2)	(13)	(33)	(31)	(41)	(43)
	Free cash flow	—	—	—	(108)	(56)	(162)	(163)	(187)	(99)	(149)
Balance, $m
Balance, $m	Working capital	—	—	—	46	27	1,010	916	503	306	20
	Total debt	—	—	—	70	68	48	43	39	35	35
	Net debt	—	—	—	(69)	(67)	(1,006)	(844)	(457)	(371)	(250)
	Shareholders’ equity	—	—	—	(232)	(285)	1,092	1,041	661	471	127
Returns, %
Returns, %	ROA	—	—	—	(70.14)	(14.14)	(40.00)	(6.49)	(15.27)	(14.97)	(26.04)
	ROIC	—	—	—	0.00	0.00	(273.14)	(33.56)	(70.95)	(182.11)	0.00
	ROE	—	—	—	121.80	23.24	(100.76)	(9.99)	(30.86)	(45.96)	(130.95)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARDT Ardent Health, Inc.	$1.7B	21.7×	7.7×	−1.40% (below 0%: shrinking)	−76.92% (below 0%: shrinking)	+121.70% (above 0%: growing)	100.00%	3.44%	Compare
SNDA Sonida Senior Living, Inc.	$1.7B	— (loss-making)	— (loss-making)	+122.02% (above 0%: growing)	n/m	−291.70% (below 0%: shrinking)	34.97%	(2.63%)	Compare
CMPS COMPASS Pathways PLC Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−4.18% (below 0%: shrinking)	—	0.00%	Compare
AMN AMN Healthcare Services Inc	$1.6B	15.0×	31.2×	+2.29% (above 0%: growing)	n/m	−389.43% (below 0%: shrinking)	30.58%	4.00%	Compare
AGL Agilon Health, Inc.	$1.5B	— (loss-making)	— (loss-making)	+7.15% (above 0%: growing)	n/m	−50.19% (below 0%: shrinking)	7.17%	0.79%
PNTG The Pennant Group, Inc.	$1.5B	44.5×	26.9×	+35.76% (above 0%: growing)	+23.81% (above 0%: growing)	−50.94% (below 0%: shrinking)	14.07%	5.77%	Compare
HCSG Healthcare Services Group, Inc.	$1.5B	12.2×	19.2×	+2.69% (above 0%: growing)	n/m	−26.02% (below 0%: shrinking)	15.89%	4.72%	Compare
NUTX Nutex Health Inc.	$1.4B	7.1×	6.3×	−13.62% (below 0%: shrinking)	n/m	+19.44% (above 0%: growing)	67.04%	57.75%	Compare
USPH U.S. Physical Therapy, Inc.	$1.3B	504×	27.7×	+8.47% (above 0%: growing)	−56.90% (below 0%: shrinking)	−8.24% (below 0%: shrinking)	19.59%	10.25%	Compare
Median of peers	$1.5B	18.4×	23.0×	+2.69%	−56.90%	−17.13%	30.58%	4.36%

All 55 Medical Care Facilities stocks →

Agilon Health, Inc. (AGL) key facts

Concern: Agilon Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.9 billion, down 2.11% from fiscal 2024.
Agilon Health, Inc. (AGL) is a Medical Care Facilities company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, AGL traded at $85.12, a market capitalization of $1.5 billion.
Return on equity was −131.0% and debt-to-equity 0.13.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 1.45 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.